DEN-181 is under clinical development by Dendright and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DEN-181’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DEN-181 (Rheumavax) is under development for the treatment of rheumatoid arthritis. The therapeutic candidate is administered intradermally and subcutaneously. The vaccine candidate is composed of autologous modified dendritic cells (DC) pulsed with a mixture of four citrullinated peptide antigens encompassing cit-vimentin, cit-fibrinogen beta chain, a cit-fibrinogen alpha chain and cit-collagen type II. It is a liposome drug product that delivers an immunomodulatory compound and an autoantigenic peptide relevant to the pathophysiology of emergent RA to cells. The therapeutic candidate is developed based on Curcusome platform technology. It was under development for the treatment of multiple sclerosis, celiac disease and type 1 diabetes.
For a complete picture of DEN-181’s drug-specific PTSR and LoA scores, buy the report here.